Alnylam shares plunge after it ends development of drug due to patient deaths | Traderszone

- Home
- TZ Newswire
- Business Features
- ETF's
- Futures
- Options
- Real Estate
- Stocks
- TZ Featured Lists
- TZ Latest News
- TZ Resources
Editorial Archives
Editorial Archives

Published in TZ Latest News 6 October, 2016 by The TZ Newswire Staff

Alnylam shares plunge after it ends development of drug due to patient deaths

Alnylam Pharmaceuticals said it would halt development of an experimental therapy for a rare genetic condition that can cause heart failure.

See also
- Next Article Hong Kong SFC Warns Against Unlicensed Brokerage CW Associates
- Previous Article Storm of obstacles in path of thousands fleeing Hurricane Matthew
Editorial Calender

October 2016

M T W T F S S

1 2

3 4 5 6 7 8 9

10 11 12 13 14 15 16

17 18 19 20 21 22 23

24 25 26 27 28 29 30

31

« Sep Nov »
Recent Tags

Abnormal Returns Active management Asia Brave New World Business Chart.ly Chicago Board Options Exchange CNBC Commodities and Futures Covestor Day Trading Derivatives Equities Exchange Exchange-traded fund Funds Gawker.com GDP Gold Gold as an investment Gross domestic product High-frequency trading Hong Kong Investing Japan Market maker May 6 2010 flash crash Mutual fund National Association of Home Builders New York Mercantile Exchange Option S&P 500 SEC Standard & Poor Stock Stocks and Bonds Stock trader StockTwits Timothy Sykes Tokyo Trade Twitter U.S. Dollar Index U.S. Securities and Exchange Commission United States dollar